# A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors

> **NCT06976437** · EARLY_PHASE1 · RECRUITING · sponsor: **YANRU WANG** · enrollment: 21 (estimated)

## Conditions studied

- B Cell Lymphoma
- Multiple Myeloma

## Interventions

- **DRUG:** RN1101 injection

## Key facts

- **NCT ID:** NCT06976437
- **Lead sponsor:** YANRU WANG
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-06
- **Primary completion:** 2027-05-20
- **Final completion:** 2027-12-30
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-07-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06976437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06976437, "A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06976437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*